Evidence map›Paper›PMID 38420030›Full record

ReviewFrontiers in public health2024

HIV/AIDS in Indonesia: current treatment landscape, future therapeutic horizons, and herbal approaches.

Jocelyn, Fadli Mubaroq Nasution, Natasya Assyifa Nasution, M Hanafi Asshiddiqi, Nidya Haschita Kimura, Madeline Hana Tasya Siburian, Zata Yumni Nabila Rusdi, Annisa Renzu Munthe, Ivina Chairenza, Michelle C F Br Ginting Munthe and 7 more

RetractedOpen access · goldAbstract readReviewRetracted Publication
In one paragraph

Review in Frontiers in public health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
9.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Exploring the dynamics of HIV and CD4Scientific reports · 2024
    Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors at 1 institution in 1 country.

JocelynFaculty of Pharmacy, Universitas Sumatera Utara, Medan, Sumatera Utara, Indonesia.
Fadli Mubaroq NasutionFaculty of Pharmacy, Universitas Sumatera Utara, Medan, Sumatera Utara, Indonesia.
Natasya Assyifa NasutionFaculty of Pharmacy, Universitas Sumatera Utara, Medan, Sumatera Utara, Indonesia.
M Hanafi AsshiddiqiFaculty of Pharmacy, Universitas Sumatera Utara, Medan, Sumatera Utara, Indonesia.
Nidya Haschita KimuraFaculty of Pharmacy, Universitas Sumatera Utara, Medan, Sumatera Utara, Indonesia.
Madeline Hana Tasya SiburianFaculty of Pharmacy, Universitas Sumatera Utara, Medan, Sumatera Utara, Indonesia.
Zata Yumni Nabila RusdiFaculty of Pharmacy, Universitas Sumatera Utara, Medan, Sumatera Utara, Indonesia.
Annisa Renzu MuntheFaculty of Pharmacy, Universitas Sumatera Utara, Medan, Sumatera Utara, Indonesia.
Ivina ChairenzaFaculty of Pharmacy, Universitas Sumatera Utara, Medan, Sumatera Utara, Indonesia.
Michelle C F Br Ginting MuntheFaculty of Pharmacy, Universitas Sumatera Utara, Medan, Sumatera Utara, Indonesia.
Putri SianiparFaculty of Pharmacy, Universitas Sumatera Utara, Medan, Sumatera Utara, Indonesia.
Surya Perdana GultomFaculty of Pharmacy, Universitas Sumatera Utara, Medan, Sumatera Utara, Indonesia.
David SimamoraFaculty of Pharmacy, Universitas Sumatera Utara, Medan, Sumatera Utara, Indonesia.
Irene Rosari UswanasFaculty of Pharmacy, Universitas Sumatera Utara, Medan, Sumatera Utara, Indonesia.
Emil SalimFaculty of Pharmacy, Universitas Sumatera Utara, Medan, Sumatera Utara, Indonesia.
Khairunnisa KhairunnisaFaculty of Pharmacy, Universitas Sumatera Utara, Medan, Sumatera Utara, Indonesia.
Rony Abdi SyahputraFaculty of Pharmacy, Universitas Sumatera Utara, Medan, Sumatera Utara, Indonesia.
University of North Sumatra · ID

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

HIV/AIDS is still a major worldwide health concern, and Indonesia is making efforts to mitigate its effects. Antiretroviral therapy (ARV), which aims to decrease viral replication, boost immunological function, and lengthen the lifespans of persons living with HIV/AIDS, is the cornerstone of Indonesia's strategy. The availability of ARV has significantly increased, yet problems including stigma and the requirement for regular medication adherence still exist. To address the broader needs of those affected by HIV/AIDS, Indonesia lays a major focus on comprehensive care, which includes mental health and social support, in addition to ARV. Data show that, despite progress, there is still a stigma surrounding HIV/AIDS, which affects patient outcomes and access to care. With vigorous research into cutting-edge antiretroviral medications and treatment techniques, Indonesia has a thriving future therapeutic landscape. The goals of these programs are to increase treatment effectiveness, decrease side effects, and increase access to cutting-edge treatments. Preventive methods, such as PrEP (pre-exposure prophylaxis), are making progress, and efforts to find a cure are gaining prominence. Notably, HIV/AIDS management plan of Indonesia heavily relies on natural remedies. Patient care incorporates traditional Indonesian medicine, such as jamu and several herbal medicines. Although there is little scientific proof to support the effectiveness of these herbal remedies, complementary and alternative therapies frequently employ them to manage symptoms and promote general wellness. In terms of the 95-95-95 targets, Indonesia is making an effort to comply with these international goals by seeking to diagnose 95% of HIV-positive individuals, provide sustained ARV to 95% of those diagnosed, and achieve viral suppression in 95% of ARV recipients. Although there are gaps in reaching these aims, progress is being made, in part because of the aforementioned challenges. In summary, Indonesia employs a multimodal approach to HIV/AIDS management, including traditional herbal cures, continuous research into cutting-edge treatments, and conventional ARV. In order to enhance overall health outcomes and create a healthier society, the future of HIV/AIDS treatment in Indonesia is concentrated on expanding therapeutic alternatives, reaching the 95-95-95 targets, decreasing stigma, and improving access to care.

Indexed as

Acquired Immunodeficiency SyndromeComplementary TherapiesHIV InfectionsAnti-Retroviral AgentsHumansIndonesiaAnti-Retroviral Agentsantiretroviral therapyherbal approachesHIV/AIDSmedication adherencepre-exposure prophylaxis

Identifiers

PMID38420030
PMCPMC10899510
OpenAlexW4391818632

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.